ChristianaCare Launches DECODR, Inc. to Bring Advanced, Accurate Gene Editing Analysis to Scientists Worldwide

ChristianaCare’s Gene Editing Institute has launched DECODR, Inc., a new for‑profit company created to expand access to one of the world’s leading software tools to evaluate the effectiveness of CRISPR gene editing. 

As a standalone company, DECODR, Inc., will continue to improve and deliver its technology to researchers across academic, nonprofit, and commercial settings, with a software program that grew out of the Gene Editing Institute’s mission to turn cutting-edge science into real-world solutions that help patients. 

According to Towards Healthcare, the human identification market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 3.17 billion in 2026 to approximately USD 6.25 billion by 2035, representing a compound annual growth rate (CAGR) of 7.84% from 2026 to 2035. Growth is driven by the increasing incidence of criminal investigations, missing person identification, and disaster victim recognition, which has driven the adoption of advanced molecular diagnostic solutions. The market is experiencing consistent growth owing to the rising demand for advanced forensic tools, expanding applications in law enforcement, and the growing importance of genetic databases.  

What Is DECODR? 

DECODR® (Deconvolution of Complex DNA Repair), Gene editing creates huge amounts of data, but analysing that data and accurately showing what edits occurred, including insertions, deletions, combined changes, and precise DNA repairs. It is software that helps scientists understand what happens to DNA after it is edited using CRISPR. 

The gene therapy development, biotechnology, and gene‑editing therapeutics, agricultural plant science, and animal model generation in academic and translational research labs, as well as by contract research organizations and contract development and manufacturing organizations that support CRISPR programs.  

The program delivers results in seconds and can shorten scientific workflows from days to hours when compared to alternative sequencing and analysis technologies.  

Associate director of technology development at the Gene Editing Institute and chief technology officer at DECODR, Inc., Pawel Bialk stated DECODR was created to solve a very real problem for researchers who need to measure CRISPR edits accurately and at scale. 

A recent report by Towards Healthcare highlights that the human identification market is witnessing growth due to the rising crime rates in the U.S., which has seen a significant increase in murder rates, prompting a surge in demand for advanced identification technologies. Technological advancements and innovations in DNA analysis, particularly next-generation sequencing, are enabling the analysis of degraded DNA samples and improving accuracy in forensic investigations.